Concept and Rationale

Gene therapy relies on the ability to deliver functional genetic material into target cells safely and efficiently. Traditional viral vectors (such as AAV, lentivirus, and adenovirus) and non-viral systems each present strengths and limitations. The NGVL concept aims to serve as a systematic “launchpad” for developing next-generation vectors that integrate the advantages of both platforms while minimizing associated risks.

The central hypothesis is that modular, engineered vector systems can be rapidly iterated and optimized using standardized design pipelines, enabling faster translation from bench to preclinical and clinical applications.

Core Components of NGVL

The NGVL framework typically includes four interconnected modules:

• Vector Engineering Module
  Development of viral and non-viral vectors with enhanced payload capacity, improved tropism, and reduced immunogenicity. This includes capsid engineering, lipid nanoparticle optimization, and hybrid vector systems.
• Genetic Payload Optimization Module
  Design of therapeutic constructs (genes, CRISPR components, regulatory elements) optimized for expression efficiency, stability, and cell-specific activation.
• Delivery and Targeting Module
  Incorporation of tissue-specific ligands, receptor targeting systems, and smart delivery vehicles to ensure precise gene delivery to diseased tissues while minimizing off-target effects.
• Evaluation and Screening Module
  High-throughput in vitro and in vivo screening platforms combined with bioinformatics and AI-driven predictive modeling to assess vector performance, safety, and biodistribution.